Prognostic factors in carcinomas of unknown primary site

被引:0
|
作者
Seve, P. [2 ,3 ]
Culine, S. [1 ]
机构
[1] CHU Henri Mondor, Med Oncol Serv, F-94010 Creteil, France
[2] Hosp Civils Lyon, Serv Med Interne, F-69288 Lyon 02, France
[3] Univ Lyon 1, Fac Med Lyon Sud, F-69622 Villeurbanne, France
关键词
Carcinoma of unknown primary (CUP); Prognostic factors;
D O I
10.1007/s10269-008-0970-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Carcinomas of unknown primary (CUP) site are a heterogeneous group of tumours with widely variable natural histories and poor survival rates. In a minority of patients, the clinical presentation similar to that of known primar cancers at an equivalent stage has resulted in the identification of subsets of patients with favourable clinical and pathological features. Their recognition is of major importance since specific management may prolong survival. For the vast majority of patients with CUP however, the identification of reliable prognostic indicators has proven challenging. A number of studies with multivariate analyses identified poor performance status, liver metastases, abnormal serum lacticodehydrogenase levels, and low serum albumin as main recurrent adverse prognostic factors. Adequate knowledge of prognostic factors may help oncologists in refining the daily management of patients, assessing the results and designing clinical research studies.
引用
收藏
页码:703 / 706
页数:4
相关论文
共 50 条
  • [21] Significance of serum tumor markers monitoring in carcinomas of unknown primary site
    Pejcic, Ivica
    Vrbic, Svetislav
    Filipovic, Sladjana
    Scekic, Mirjana
    Petkovic, Ivan
    Pejcic, Ljiljana
    Djenic, Nebojsa
    VOJNOSANITETSKI PREGLED, 2010, 67 (09) : 723 - 731
  • [22] Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site
    Seve, Pascal
    Ray-Coquard, Isabelle
    Trillet-Lenoir, Veronique
    Sawyer, Michael
    Hanson, John
    Broussolle, Christiane
    Negrier, Sylvie
    Dumontet, Charles
    Mackey, John R.
    CANCER, 2006, 107 (11) : 2698 - 2705
  • [23] Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site
    Trivanovic, Dragan
    Petkovic, Marija
    Stimac, Davor
    CANCER, 2007, 109 (12) : 2623 - 2624
  • [24] Inflammation as a validated prognostic determinant in carcinoma of unknown primary site
    Mohamed, Z.
    Pinato, D. J.
    Mauri, F. A.
    Chen, K-W
    Chang, P. M-H
    Sharma, R.
    BRITISH JOURNAL OF CANCER, 2014, 110 (01) : 208 - 213
  • [25] Inflammation as a validated prognostic determinant in carcinoma of unknown primary site
    Z Mohamed
    D J Pinato
    F A Mauri
    K-W Chen
    P M-H Chang
    R Sharma
    British Journal of Cancer, 2014, 110 : 208 - 213
  • [26] Prognostic Factors in Patients With Cancer of Unknown Primary (CUP)
    Petrakis, D.
    Voulgaris, E.
    Pentheroudakis, G.
    Pavlidis, N.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S673 - S673
  • [27] Malignant melanoma of unknown primary site (MUP). Systematic review of the literature with emphasis on survival and prognostic factors
    Kamposioras, K.
    Pentheroudakis, G.
    Pectasides, D.
    Pavlidis, N.
    EJC SUPPLEMENTS, 2009, 7 (02): : 589 - 589
  • [28] PROGNOSTIC AND PREDICTIVE SIGNIFICANCE OF PHARMACOGENETIC ANALYSIS IN PATIENTS WITH CARCINOMAS OF UNKNOWN PRIMARY (CAUP)
    Papadaki, C.
    Pentheroudakis, G.
    Cervantes Ruiperez, A.
    Lagoudaki, E.
    Petrakis, D.
    Souglakos, J.
    Braun, E. R.
    Georgoulias, V.
    Mavroudis, D.
    Pavlidis, N.
    ANNALS OF ONCOLOGY, 2012, 23 : 381 - 381
  • [29] PROGNOSTIC SIGNIFICANCE OF GENE EXPRESSION PROFILE IN PATIENTS WITH CARCINOMAS OF UNKNOWN PRIMARY (CAUP)
    Souglakos, J.
    Pentheroudakis, G.
    Papadaki, C.
    Cervantes, A.
    Petrakis, D.
    Roodriguez-Braun, E.
    Lagoudaki, E.
    Georgoulias, V.
    Mavroudis, D.
    Pavlidis, N.
    ANNALS OF ONCOLOGY, 2010, 21 : 55 - 55
  • [30] Chemotherapy in carcinomas of unknown primary site (CUP): A high dose intensity policy
    Culine, S
    Fabbro, M
    Ychou, M
    Romieu, G
    Cupissol, D
    Pujol, H
    ANNALS OF ONCOLOGY, 1998, 9 : 49 - 49